Dosing begins in trial testing Enhertu for ovarian cancer
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Anito-cel shows high 2-year survival rate in myeloma trial: Data
Most people with hard-to-treat myeloma were still alive and free from disease progression two years after treatment with anito-cel (anitocabtagene autoleucel), an experimental cell…
CLN-049 now has FDA fast track designation for hard-to-treat AML
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine CLN-049, which is being developed as a potential treatment…
FDA fast tracks zotiraciclib for treating aggressive brain cancer
The U.S. Food and Drug Administration (FDA) has granted fast track status to zotiraciclib (ZTR/TG02) — an oral medication that targets pathways in the body…
New therapy DT2216 tackles tough-to-treat ovarian cancer
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
California myeloma clinic reports ‘unprecedented’ patient survival
Most myeloma patients who started treatment at the Berenson Cancer Center — a clinic in California that specializes in myeloma care — lived…
New center promotes advocacy for gynecological cancer patients
The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by…
New ‘powerful’ lab test will help researchers explore blood cancer
Mission Bio has debuted a new laboratory test that enables researchers to simultaneously detect alterations in the genetic code and changes in genetic activity…
Case: Growth on pancreas shows estrogen link to pancreatic cancer
Changes in how cells respond to the hormone estrogen may underlie the development of certain forms of pancreatic cancer. That’s according to findings from…
Glioma trial of intranasal therapy NEO100 fills all patient slots
Neonc Technologies has completed enrollment for its Phase 2a clinical trial of NEO100, an intranasal treatment for high-grade glioma, the company announced. This follows…
